Nuvation Bio (NUVB) Proxy filing summary
Event summary combining transcript, slides, and related documents.
Proxy filing summary
10 Apr, 2026Executive summary
Annual Meeting scheduled for May 21, 2026, via live webcast, with record date of March 25, 2026.
Stockholders will vote on director elections, ratification of KPMG LLP as auditor, and an advisory say-on-pay vote.
Voting instructions provided for online, phone, and mail participation; quorum requirements detailed.
Board recommends voting in favor of all proposals.
Voting matters and shareholder proposals
Three proposals: election of three directors, ratification of KPMG LLP as auditor for 2026, and advisory approval of executive compensation.
Class A and Class B stockholders vote together for two directors; Class B stockholders vote separately for one director.
Stockholder proposals for the 2027 meeting must be submitted by December 11, 2026, for inclusion in proxy materials.
Board of directors and corporate governance
Board consists of seven members, divided into three classes with staggered three-year terms.
Majority of directors are independent per NYSE standards; Dr. Hung serves as Board Chair, Mr. Bazemore as Lead Independent Director.
Board committees: audit, compensation, and nominating/corporate governance, each with defined charters and responsibilities.
Board and committees met regularly in 2025, with all directors attending at least 75% of meetings.
Latest events from Nuvation Bio
- IBTROZI's launch and pipeline progress drive growth in targeted oncology markets.NUVB
Corporate presentation - Q2 2026 revenue rose to $31.7M, driven by IBTROZI growth and Eisai partnership.NUVB
Q2 2026 - IBTROZI's global success and a robust pipeline drive growth in high-value oncology markets.NUVB
Corporate presentation - Taletrectinib leads a robust pipeline with best-in-class data and a commercial launch expected in 2025.NUVB
Jefferies London Healthcare Conference 2024 - IBTROZI’s global approvals and strong efficacy drive growth, with safusidenib advancing in pivotal trials.NUVB
Corporate presentation - IBTROZI's superior efficacy and CNS benefits drive ROS1 market leadership; pipeline and financials remain strong.NUVB
Jefferies Global Healthcare Conference 2026 - IBTROZI's first-line growth accelerates as pipeline assets advance in high-need glioma settings.NUVB
7th Annual Oncology Innovation Summit: Insights for ASCO & EHA - IBTROZI and safusidenib drive growth with best-in-class data and major upcoming clinical catalysts.NUVB
H.C. Wainwright 4th Annual BioConnect Investor Conference - All proposals passed, including director elections and auditor ratification, with strong quorum.NUVB
AGM 2026 - First-line oncology drug adoption is accelerating, with robust growth and strong clinical results.NUVB
TD Cowen 46th Annual Health Care Conference